Saniona: A leading biotech company within the field of ion channel-dependent diseases




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Saniona: A leading biotech company within the field of ion channel-dependent diseases
Released on: October 11, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Saniona is a research and development company focused on drugs for central nervous system diseases, autoimmune diseases, metabolic diseases and pain management.
  • Summary
  • Participants
  • Company
Saniona is a research and development company focused on drugs for central nervous system diseases, autoimmune diseases, metabolic diseases and pain management. Jørgen Drejer, President of Saniona talks to Adrian Dawkes about the companies extensive portfolio of potential drug candidates in preclinical and clinical phase.
Dr. Drejer was a co-founder of NeuroSearch in 1989 serving as Executive Vice President and Director of Drug Discovery. Dr. Drejer is a serial entrepreneur and also co-founded - or assisted in founding - several other Biotech companies, including, NsGene, Sophion Biosciences, Antalium (Canada); Poseidon Pharmaceuticals, and Azign. He is on the Board of Directors at Atonomics, Delta and Delta Reader. He also holds a board seat at the Danish National Research Council for Independent Research and is a member of the Danish Academy for Technical Sciences. Dr. Drejer is the author of more than 75 peer-reviewed articles and holds a Ph.D. in Neurobiology from the Royal Danish School of Pharmacy (now University of Copenhagen).
Saniona is a research and development company focused on drugs for central nervous system diseases, autoimmune diseases, metabolic diseases and pain management. The company has an extensive portfolio of potential drug candidates in preclinical or clinical phase. The research focuses on ion channels that constitute a unique class of proteins that enable and control the passage of ions in the cell membrane. The company cooperates with Boehringer Ingelheim GmbH, Upsher-Smith Laboratories, Inc., Productos Medix SA de SV and Sanionas Boston-based spinout Ataxion Inc., which is financed by Atlas Venture Inc. and Biogen Inc. Saniona has its office in Copenhagen, where the company has a research site of a high international standard. Saniona is listed on Nasdaq OMX First North Premier and has approximately 4400 shareholders. Pareto Securities is Certified Adviser for Saniona. The share is traded under the ticker SANION.